These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 31293154)
1. Characterization of Genetic Variation in CYP3A4 on the Metabolism of Cabozantinib in Vitro. Lin QM; Li YH; Lu XR; Wang R; Pang NH; Xu RA; Cai JP; Hu GX Chem Res Toxicol; 2019 Aug; 32(8):1583-1590. PubMed ID: 31293154 [TBL] [Abstract][Full Text] [Related]
2. Functional evaluation of vandetanib metabolism by CYP3A4 variants and potential drug interactions in vitro. Han M; Zhang X; Ye Z; Wang J; Qian J; Hu G; Cai J Chem Biol Interact; 2021 Dec; 350():109700. PubMed ID: 34648813 [TBL] [Abstract][Full Text] [Related]
3. Functional characterization of 27 CYP3A4 protein variants to metabolize regorafenib in vitro. Li YH; Lin QM; Pang NH; Zhang XD; Huang HL; Cai JP; Hu GX Basic Clin Pharmacol Toxicol; 2019 Oct; 125(4):337-344. PubMed ID: 31058459 [TBL] [Abstract][Full Text] [Related]
4. Functional assessment of the effects of CYP3A4 variants on acalabrutinib metabolism in vitro. Han M; Qian J; Ye Z; Xu R; Chen D; Xie S; Cai J; Hu G Chem Biol Interact; 2021 Aug; 345():109559. PubMed ID: 34153224 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK. Nguyen L; Holland J; Miles D; Engel C; Benrimoh N; O'Reilly T; Lacy S J Clin Pharmacol; 2015 Sep; 55(9):1012-23. PubMed ID: 25854986 [TBL] [Abstract][Full Text] [Related]
6. Functional assessment of Fang P; Tang PF; Xu RA; Zheng X; Wen J; Bao SS; Cai JP; Hu GX Drug Des Devel Ther; 2017; 11():3503-3510. PubMed ID: 29263648 [TBL] [Abstract][Full Text] [Related]
7. Functional Measurement of CYP2C9 and CYP3A4 Allelic Polymorphism on Sildenafil Metabolism. Tang PF; Zheng X; Hu XX; Yang CC; Chen Z; Qian JC; Cai JP; Hu GX Drug Des Devel Ther; 2020; 14():5129-5141. PubMed ID: 33262574 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of Recombinant CYP3A4 Variants on the Metabolism of Oxycodone In Vitro. Cai Y; Lin Q; Jin Z; Xia F; Ye Y; Xia Y; Papadimos TJ; Wang Q; Hu G; Cai J; Chen L Chem Res Toxicol; 2021 Jan; 34(1):103-109. PubMed ID: 33393779 [TBL] [Abstract][Full Text] [Related]
9. Functional Analysis of Wild-Type and 27 CYP3A4 Variants on Dronedarone Metabolism Wang CC; Lan T Curr Drug Metab; 2022; 23(7):562-570. PubMed ID: 35702776 [TBL] [Abstract][Full Text] [Related]
10. In Vitro Kinetic Characterization of Axitinib Metabolism. Zientek MA; Goosen TC; Tseng E; Lin J; Bauman JN; Walker GS; Kang P; Jiang Y; Freiwald S; Neul D; Smith BJ Drug Metab Dispos; 2016 Jan; 44(1):102-14. PubMed ID: 26512042 [TBL] [Abstract][Full Text] [Related]
11. Effects of Clarithromycin and Ketoconazole on FK506 Metabolism in Different CYP3A4 Genotype Recombinant Metabolic Enzyme Systems. Wen J; Xiao Y; Zhao M; Yang C; Hu W Curr Drug Metab; 2024; 25(2):174-177. PubMed ID: 38523538 [TBL] [Abstract][Full Text] [Related]
12. The effect of gene polymorphism on ticagrelor metabolism: an Hu X; Wang P; Zeng D; Hu GX PeerJ; 2024; 12():e18109. PubMed ID: 39346054 [TBL] [Abstract][Full Text] [Related]
13. Genetic variations of CYP3A4 on the metabolism of itraconazole in vitro. Xie SL; Zhu X; Gao N; Lin Q; Chen C; Yang YJ; Cai JP; Hu GX; Xu RA Food Chem Toxicol; 2023 Nov; 181():114101. PubMed ID: 37863381 [TBL] [Abstract][Full Text] [Related]
14. Variation in the Response of Clozapine Biotransformation Pathways in Human Hepatic Microsomes to CYP1A2- and CYP3A4-selective Inhibitors. Murray M; Zhang WV; Edwards RJ Basic Clin Pharmacol Toxicol; 2018 Apr; 122(4):388-395. PubMed ID: 29155491 [TBL] [Abstract][Full Text] [Related]
15. Functional Characterization of 22 CYP3A4 Protein Variants to Metabolize Ibrutinib In Vitro. Xu RA; Wen J; Tang P; Wang C; Xie S; Zhang BW; Zhou Q; Cai JP; Hu GX Basic Clin Pharmacol Toxicol; 2018 Apr; 122(4):383-387. PubMed ID: 29117640 [TBL] [Abstract][Full Text] [Related]
17. Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087). Haigentz M; Lee JY; Chiao EY; Aboulafia DM; Ratner L; Ambinder RF; Baiocchi RA; Mitsuyasu RT; Wachsman W; Sparano JA; Rudek MA Clin Cancer Res; 2023 Dec; 29(24):5038-5046. PubMed ID: 37523145 [TBL] [Abstract][Full Text] [Related]
18. Functional characterization of 21 CYP3A4 variants on amiodarone metabolism in vitro. Yang CC; Zheng X; Liu TH; Wang CC; Tang PF; Chen Z; Zhang BW; Fang P; Hu GX; Cai JP Xenobiotica; 2019 Jan; 49(1):120-126. PubMed ID: 29394111 [TBL] [Abstract][Full Text] [Related]
19. Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam. van Waterschoot RA; Rooswinkel RW; Sparidans RW; van Herwaarden AE; Beijnen JH; Schinkel AH Drug Metab Dispos; 2009 Dec; 37(12):2305-13. PubMed ID: 19752211 [TBL] [Abstract][Full Text] [Related]
20. Functional characteristics of CYP3A4 allelic variants on the metabolism of loperamide in vitro. Lin QM; Li YH; Liu Q; Pang NH; Xu RA; Cai JP; Hu GX Infect Drug Resist; 2019; 12():2809-2817. PubMed ID: 31571937 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]